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Background: As major regulators of normal chondrogenesis, the bone morphogenic protein (BMP) and
transforming growth factor β (TGFB) signaling pathways may be involved in the development and progression of
central chondrosarcoma. In order to uncover their possible implication, the aim of this study was to perform a
systematic quantitative study of the expression of BMPs, TGFBs and their receptors and to assess activity of the
corresponding pathways in central chondrosarcoma.
Methods: Gene expression analysis was performed by quantitative RT-PCR in 26 central chondrosarcoma and 6
healthy articular cartilage samples. Expression of endoglin and nuclear localization of phosphorylated Smad1/5/8
and Smad2 was assessed by immunohistochemical analysis.
Results: The expression of TGFB3 and of the activin receptor-like kinase ALK2 was found to be significantly higher
in grade III compared to grade I chondrosarcoma. Nuclear phosphorylated Smad1/5/8 and Smad2 were found in all
tumors analyzed and the activity of both signaling pathways was confirmed by functional reporter assays in
2 chondrosarcoma cell lines. Immunohistochemical analysis furthermore revealed that phosphorylated Smad1/5/8
and endoglin expression were significantly higher in high-grade compared to low-grade chondrosarcoma and
correlated to each other.
Conclusions: The BMP and TGFβ signaling pathways were found to be active in central chondrosarcoma cells. The
correlation of Smad1/5/8 activity to endoglin expression suggests that, as described in other cell types, endoglin
could enhance Smad1/5/8 signaling in high-grade chondrosarcoma cells. Endoglin expression coupled to
Smad1/5/8 activation could thus represent a functionally important signaling axis for the progression of
chondrosarcoma and a regulator of the undifferentiated phenotype of high-grade tumor cells.
Keywords: Conventional central chondrosarcoma, Bone tumor, Chondrogenic differentiation, Bone morphogenic
proteins, Transforming growth factor βBackground
Conventional central chondrosarcomas are cartilaginous
tumors which arise centrally within the medullar cavity
of bone. They represent 75% of all malignant cartilage
tumors. Low-grade chondrosarcoma displays a hyaline
cartilage matrix with low cell density, and an abundance* Correspondence: wiltrud.richter@med.uni-heidelberg.de
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reproduction in any medium, provided the orof hyaline cartilage matrix, no mitoses and cells with a
chondrocyte-like morphology. While these tumors gen-
erally do not metastasize, they can progress to high-
grade chondrosarcomas which are characterized by a
muco-myxoid matrix, a high density of cells with
increased mitotic rates and elevated vascularization. At
the periphery of the lobules of high-grade chondrosar-
coma, cells may become spindle-shaped [1]. These
tumors often metastasize, are considered resistant to
chemotherapy and radiotherapy and the 10 years sur-
vival rate is only 29% for grade III chondrosarcoma [2].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the matrix in central chondrosarcoma suggest par-
allels between differentiation stages of tumor cells and
of normal chondrocytes [3]. Gene expression profiles
have indicated that during progression chondrosar-
coma cells shift from a differentiated state in low-
grade tumors to a state more similar to early
chondrogenic differentiation stages of mesenchymal
precursor cells in high-grade tumors [4]. The correl-
ation of the differentiation stage of chondrosarcoma
cells to the degree of malignancy of the tumors indi-
cates that signaling pathways that control normal
chondrogenesis may have a regulatory function in the
progression of these tumors.
Bone morphogenic protein (BMP) and transforming
growth factor β (TGFβ) signaling is one of the crucial
pathways controlling chondrogenic differentiation in the
normal growth plate [5]. The main paracrine factors of
the TGFβ superfamily relevant for cartilage and bone
formation are BMP2, BMP4, BMP6, BMP7, TGFβ1,
TGFβ2 and TGFβ3. Signaling is initiated when BMPs
bind to the type II receptor BMPRII and TGFβ mole-
cules to TGFBRII. These receptors are transmembrane
serine/threonine kinases which upon binding of a ligand
recruit the type I receptors ALK1, ALK2, ALK3 or ALK6
for BMPRII and ALK1 or ALK5 for TGFBRII, leading to
phosphorylation and activation of the type I receptor
kinases. The activated type I receptors in turn phosphor-
ylate intracellular Smad molecules which translocate in
the nucleus and modulate the expression of target genes.
The activation of ALK1/2/3/6 induces the phosphoryl-
ation of Smad1, Smad5 and Smad8, while ALK5 induces
Smad2 and Smad3 [6,7]. BMPs thus activate Smad1/5/8
while TGFβ, depending on the type I receptor recruited,
can activate either Smad2/3 or Smad1/5/8. In endothe-
lial cells and chondrocytes, the TGFβ/ALK1/Smad1 sig-
naling axis appears to be favored in presence of the
TGFβ co-receptor endoglin, also known as CD105 [7,8].
As shown by detection of nuclear Smad proteins, the
TGFβ and BMP signaling pathways are active in most
cells of the growth plate and they are controlled by tight
temporal and local patterns of expression of the factors
of the TGFβ superfamily and of their receptors [9]. In
central chondrosarcoma TGFβ signaling is active accord-
ing to detection of nuclear phosphorylated Smad2. A
role of this pathway in tumor progression was suggested
as PAI1, a target gene of TGFβ/Smad2/3, showed higher
levels in high grade tumors [10]. In an immunohisto-
chemical study, a correlation of TGFβ1 and TGFβ2 to
the grade of chondrosarcoma has been described [11]. In
contrast to these results suggesting that TGFβ signaling
could be involved in chondrosarcoma progression, data
demonstrating active BMP signaling in chondrosarcoma
tissue are lacking. While one immunohistochemicalstudy found no BMPs in human conventional chondro-
sarcoma tissue [12], one RT-PCR based gene expression
analysis detected expression of BMP2, 4, 6 and BMPRII
[13]. The migratory effect of BMP2 on chondrosarcoma
cell lines, however, suggests a role of BMP signaling in
progression [14].
As major regulators of normal chondrogenesis, the
BMP and TGFβ signaling pathways could play an active
role in the progression of chondrosarcoma. Perturba-
tions of these pathways are known to result in disorders
ranging from vascular and skeletal disease to cancer [6].
In order to uncover a potential implication in chondro-
sarcoma, the aim of this project was to perform a sys-
tematic quantitative study of the expression of BMPs,
TGFβs and their receptors and to assess activity of the
corresponding signaling pathways in central chondrosar-
coma cells.
Results
Expression of BMP and TGFβ ligands and receptors in
central chondrosarcoma
The expression of genes for BMP and TGFβ ligands and
receptors was measured in central chondrosarcoma and
normal cartilage samples by quantitative RT-PCR
(Figure 1). All of the genes analyzed were found to be
expressed in chondrosarcoma samples. While among
the ligands analyzed the BMP2, BMP4, BMP6, BMP7,
TGFB1 and TGFB2 genes did not show significant
differences between chondrosarcomas of different histo-
logical grades, TGFB3 was significantly higher expressed
in grade III compared to grade I chondrosarcoma (2-fold,
p=0.006). From the receptors analyzed, only the type I
receptor ALK2 showed differential expression and was
significantly higher in grade III than in grade I chon-
drosarcoma (2.5-fold, p=0.012).
Compared to normal cartilage, chondrosarcoma showed
altered expression levels for BMP2 and BMP7. BMP2
was significantly higher expressed in normal cartilage
samples than in chondrosarcoma (37.8-fold, p<0.001),
while BMP7 was not detected or found at very low ex-
pression levels in normal cartilage samples and was
significantly higher expressed in chondrosarcoma (29.4-
fold, p=0.005). The expression of BMP6 (data not
shown) was similar in all sample groups.
Activity of Smad1/5/8 and Smad2 in central
chondrosarcoma samples
In order to establish whether the BMP and TGFβ signal-
ing pathways are active in central chondrosarcoma, the
presence of nuclear phosphorylated Smad1/5/8 and
Smad2 was evaluated by immunohistochemical analysis.
Phosphorylated Smad1/5/8 and Smad2 was detected in
all chondrosarcoma samples analyzed (Figure 2A, B).
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Figure 1 Quantitative RT-PCR analysis of members of the BMP and TGFβ family in central chondrosarcoma. Expression levels of BMP2,
BMP4, BMP7, TGFB1, TGFB2, TGFB3, ACVRL1/ALK1, ACVR1/ALK2 and TGFBR1/ALK5 were assessed in normal cartilage (CART; n=6), grade I (CCSI;
n=10), grade II (CCSII; n=10) and grade III (CCSIII; n=7) central chondrosarcoma samples and are shown as percentage of the mean expression
levels of the reference genes. The median relative expression levels in chondrosarcoma and cartilage samples are represented by solid black lines,
the boxes represent the interquartile range (IQR) extending between the 25th and 75th percentile and the whiskers extend to a maximum of
1.5 IQR. Outlier values are shown as empty circles. Statistical analysis is based on the non-parametric Mann–Whitney test after bonferroni
correction (p<0.0125). # indicates significant difference in comparison to grade III; * indicates significant difference in comparison to all CCS.
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in high-grade tumors compared to low grade while for
highly phosphorylated Smad2 there was only a trend
which did not reach significance (Table 1). There was a
trend close to significance for a longer metastasis-free
survival in patients with low phosphorylated Smad2, cor-
responding to a sum score lower or equal to 3 (p=0.055)(Figure 2D). This correlation was not independent from
the histopathological grade of the tumors.
Expression of the co-receptor endoglin
Endoglin / CD105 is a TGFβ co-receptor with the ability
to modulate TGFβ signaling through Smad1/5/8 or


























Figure 2 Immunohistochemical analysis of phosphorylated Smad1/5/8, phosphorylated Smad2 and endoglin in central
chondrosarcoma samples. A grade III central chondrosarcoma with highly nuclear phosphorylated Smad1/5/8 (A) and highly nuclear
phosphorylated Smad2 (B) is shown. C: grade II central chondrosarcoma with high endoglin expression. Note the positivity of the vessels in the
right lower corner. Kaplan-Meier analysis of metastasis-free survival in relation to sum score of tumor biopsies for phosphorylated Smad2 (D) and
endoglin / CD105 (E) is shown. High pSmad2 or CD105 designate tumor samples with a sum score higher than 3 for the corresponding antibody
and survival is shown with a broken line. Survival for patients with low pSmad2 or CD105 is shown with a solid line. The p-values of
corresponding log-rank tests are shown. F. Correlation between endoglin / CD105 expression and phosphorylated Smad1/5/8. The percentages
of samples with highly (+) or low (−) phosphorylated Smad1/5/8 among samples with high (+) or low (−) endoglin / CD105 are shown.
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fluence TGFβ signaling in chondrosarcoma, we have
assessed its expression in chondrosarcoma by immuno-
histochemical analysis. Endoglin is an established marker
of tumor vasculature [16]. Endoglin was detected in the
cytoplasm and on the membrane of tumor and vascular
cells. Only expression in tumor cells and not in theTable 1 Scoring results of the immunohistochemical staining
Diagnosis pSmad1/5/8
Higha % p-valueb Higha
total 13 / 25 52.0 15 / 24
CCS I 2 / 9 22.2 4 / 10
CCS II 7 / 10 70.0 6 / 8
CCS III 4 / 6 66.7 5 / 6
high gradec 11 / 16 68.8 0.04 11 / 14
a: number of tumor samples with high expression defined as showing a total sum s
b: p-value of the Fisher’s exact test for the comparison of the corresponding sample
c: high grade: grade II and grade III.vasculature was scored in this study (Figure 2C). Only
one grade I chondrosarcoma showed a sum score for
endoglin higher than 3 and high endoglin expression
was significantly more frequent in high-grade tumors
(Table 1). From the 10 chondrosarcoma samples with
high endoglin expression, 9 showed endoglin expression
in more than 50% of tumor cells. There was a trendin central chondrosarcoma
pSmad2 Endoglin / CD105
% p-valueb Higha % p-valueb
62.5 11 / 26 42.3
40.0 1 / 9 11.1
75.0 7 / 10 70.0
83.3 3 / 6 50.0
78.6 0.09 10 / 16 62.5 0.03
core higher than 3.
group with CCS I. Significant p-values are shown in bold.
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in patients with high endoglin expression in more than
50% of the tumor cells (p=0.052) (Figure 2E). This cor-
relation was not independent from the histopathological
grade of the tumors. Notably, among the samples with
low endoglin expression only 33% showed highly phos-
phorylated Smad1/5/8 while from the samples with high
endoglin expression more than 80% also showed highly
phosphorylated Smad1/5/8 (Figure 2F). High endoglin
expression correlated with highly phosphorylated
Smad1/5/8 (p=0.036, Pearson’s chi-square test) but not
with highly phosphorylated Smad2.
Activity of Smad1 and Smad2 in chondrosarcoma
cell lines
Functional activity of the TGFβ- and BMP pathways was
tested in the chondrosarcoma cell lines SW1353 and
JJ012 using luciferase reporter assays with two reporter
plasmids carrying pSmad2 (CAGA-luc) and pSmad1
(BRE-luc) responsive promoter elements (Figure 3).
Pathway activity was shown by activation of the lucifer-
ase reporter genes, as shown by bioluminescence. Bio-
luminescence intensity could be inhibited by specific
inhibitors, SB-431542 for TGFβ (Figure 3A) or LDN-
193189 for BMP (Figure 3C). Stimulation of the path-


































Figure 3 TGFβ and BMP pathway activity and its effect on proliferatio
The Y-axis is in percentage of luciferase activity with untreated cells set to
TGFβ inhibitor SB-431542 or with TGFβ1, to stimulate the pathway B: Prolif
TGFβ inhibitor or stimulator in two chondrosarcoma cell lines, nor in C2C1
in A. Inhibition of BMP with three different concentrations of LDN-193189 o
not affected by manipulation of BMP pathway activity.BMP4 (Figure 3C). There was more variation in
SW1353 than JJ012 in stimulation of both pathways
when comparing three separate assays. Despite respon-
siveness of chondrosarcoma cells to specific manipula-
tion of TGFβ and BMP activity there was no effect on
proliferation of the cells upon inhibition or stimulation
of the pathways (Figure 3B, D).
Discussion
We have shown for the first time that the BMP signaling
pathway is active in conventional central chondrosar-
coma and that the activity correlates to the histopatho-
logical grade of the tumors as there were significantly
more high-grade than low-grade chondrosarcomas with
highly nuclear phosphorylated Smad1/5/8. Nuclear
phosphorylated Smad2 was also detected but did not
correlate to grade. Activity of both signaling pathways
was furthermore confirmed through functional assays in
2 chondrosarcoma cell lines. Both pathways were found
to be inducible upon stimulation with TGFβ1 or BMP4.
Interestingly, changes in pathway activity did not affect
cell proliferation.
Smad1/5/8 activation can on one hand be driven by
BMPs through the ALK1/2/3/6 receptors. Our gene ex-
pression analysis of BMPs suggests that transcriptional




















n. A: TGFβ pathway activity assayed using CAGA-luc reporter assay.
100%. Cells were treated with three different concentrations of the
eration of chondrosarcoma cells is not affected by treatment with
2 cells. C: BMP pathway assayed using BRE-luc reporter assay, shown as
r stimulation with BMP4. D: Proliferation of chondrosarcoma cells is
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tor ALK2 in high-grade chondrosarcoma could however
contribute to enhanced BMP signaling and phosphory-
lated Smad1/5/8 in these tumors compared to grade I.
On the other hand, Smad1/5/8 can also be activated by
TGFβ driven ALK1 activation as it has been shown in
endothelial cells, neurons, hepatic stellate cells and
chondrocytes [7]. In that case, elevated TGFβ3 expres-
sion in grade III chondrosarcoma compared to grade I
could contribute to Smad1/5/8 activation in these
tumors. Our gene expression profiles suggest that the
BMP and TGFβ signaling pathways are regulated very
differently between normal cartilage and chondrosar-
coma. As the crosstalk between TGFβ and BMP signal-
ing pathways is known to be highly context-dependent
[17], it should be elucidated whether mechanisms
described in chondrocytes could also be relevant in
chondrosarcoma cells. This could be performed in the
chondrosarcoma cell lines, for which we have shown ac-
tivity of both signaling pathways.
In endothelial cells, it has been described that TGFβ/
ALK5/Smad2/3 signaling antagonizes TGFβ/ALK1/
Smad1, and that the balance of TGFβ/ALK1 versus
TGFβ/ALK5 represents a determinant of the pro- and
anti-angiogenic effects of TGFβ [7]. It has also been pro-
posed that the ratio of ALK1/ALK5 expression is a de-
terminant of TGFβ signaling in chondrocytes and that
high ratios result in a stronger activation of Smad1/5/8
[18]. ALK5 was significantly lower expressed in chon-
drosarcoma in comparison to cartilage while expression
levels of ALK1 were equal. The ALK1/ALK5 ratio in
chondrosarcoma could thus favor Smad1 activation in
comparison to normal cartilage. Smad1/5/8 signaling is
strongly associated with chondrocyte terminal differenti-
ation and hypertrophy [18]. Transgenic mouse models
have shown that a deletion of Smad1 and Smad 5 results
in chondrodysplasia and inhibition of the differentiation
of proliferating chondrocytes [19,20]. However, in chon-
drosarcoma no hypertrophic differentiation occurs and
we have observed that phosphorylated Smad1/5/8 was
elevated in high-grade tumors with a less differentiated
phenotype. Other mechanisms such as elevated PTHrP
signaling in chondrosarcoma may be blocking hyper-
trophy in these tumors [21].
The TGFβ co-receptor endoglin has been described as
a central modulator of these signaling pathways in endo-
thelial cells and chondrocytes [7,8]. In human articular
chondrocytes, endoglin interacts with ALK1 [22] and
was shown to enhance TGFβ1-induced Smad1/5 phos-
phorylation and to inhibit TGFβ1-induced Smad2 phos-
phorylation [8]. In central chondrosarcoma, we found
significantly higher expression of endoglin in high-grade
tumors and a correlation of endoglin expression to
Smad1/5/8 activity. This correlation suggests thatendoglin expression in high-grade chondrosarcoma
could represent a determinant of elevated Smad1/5/8 ac-
tivation in these tumors. This could involve TGFβ as
well as BMP signaling, as in Ewing sarcoma and melan-
oma cell lines endoglin was shown to lead also to higher
BMP induced Smad1 phosphorylation [23]. On the other
hand, endoglin is not exclusively modulating the Smad1/
5/8 activation. In bone marrow stromal cells, endoglin
appears to be a positive regulator of both ALK1/Smad1/
5/8 and ALK5/Smad2 pathways [24]. The dissection of
signaling pathways in chondrosarcoma cells would be
necessary to determine whether the correlation of endo-
glin expression to Smad1/5/8 phosphorylation in these
cells truly reflects an enhanced activation of this signal-
ing axis in high grade chondrosarcoma.
Endoglin / CD105 is one of the classical markers
expressed by mesenchymal stem cells and used for the
definition of these cells [25]. Endoglin expression is up-
regulated during the dedifferentiation of chondrocytes
[26] and conversely down-regulated during the chondro-
genic differentiation of mesenchymal stem cells [27]. In
bone marrow stromal cell lines, endoglin was shown to
stimulate proliferation [24]. In this context, thus, endo-
glin and Smad1 signaling correlate to undifferentiated
states of proliferating chondrogenic precursors, which is
in line with higher expression levels in high-grade chon-
drosarcoma. Our reporter assay indicates that the Smad1
and Smad2 signaling pathways may not be relevant for
proliferation of chondrosarcoma cells. Thus, while endo-
glin / Smad1 signaling seem important for loss of differ-
entiation, it is not crucial for proliferation.
Endoglin has furthermore been described to have a
pivotal function in vascular development and disease
[28]. Endoglin expression is stimulated by hypoxia
through the transcription factor HIF1α [29]. It is a mar-
ker of activated endothelial cells and its expression has
been established as a specific marker for tumor endothe-
lium in several tumor types [16]. Its expression was
however not found exclusively in tumor endothelium
but also in tumor cells in melanoma, ovary and prostate
tumors [28] and now in chondrosarcoma. We have pre-
viously described a constitutive activation of HIF1α in
high-grade chondrosarcoma as well as elevated expres-
sion of HIF1α target genes in these tumors [30]. The ex-
pression pattern of endoglin, as a further HIF1α target
gene, is in line with these results. Therefore, the hypoth-
esis can be made that endoglin could represent an im-
portant mediator of tumor angiogenesis in high-grade
chondrosarcoma. It is known that high grade chondro-
sarcomas demonstrate increased microvessel density
[30,31] and this phenomenon is also clinically used in
dynamic MRI and to diagnose chondrosarcoma. A cor-
relation between microvessel density and endoglin is
therefore likely, but would not prove a causal relation
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angiogenesis and endoglin expression could only be
approached in vitro in chondrosarcoma cells and animal
models.
Since central chondrosarcoma is a rare tumor type
and the isolation of good quality RNA is difficult due to
low cellularity and extracellular matrix [32], one limita-
tion of this study is the restricted number of samples
which allowed reaching only levels of significance close
to the threshold. The analysis of larger patient groups
would be necessary to establish the robustness of the
correlations found in this study and would especially be
interesting to assess whether high endoglin expression
significantly correlates to a high tumor vascularization
and to a low metastasis-free survival.
Conclusions
We have shown that the BMP and TGFβ signaling path-
ways are active in conventional central chondrosarcoma
and that phosphorylated Smad1/5/8 and endoglin ex-
pression were significantly higher in high-grade com-
pared to low-grade chondrosarcoma and correlated to
each other. This correlation suggests that, as described
in other cell types, endoglin could enhance Smad1/5/8
signaling in high-grade chondrosarcoma cells. Endoglin
expression coupled to Smad1/5/8 activation could thus
represent a functionally important signaling axis for the
progression of chondrosarcoma and possibly a regulator
providing a link between the undifferentiated phenotype
of tumor cells in high-grade chondrosarcoma and the
angiogenic status of these tumors. From our study it
appears that both ALK1 and ALK2 could be type I
receptors implicated in this signaling axis. Pharmaco-
logical targeting of ALK1 in a mouse model for endo-
crine pancreatic tumorigenesis and of ALK2 in ovarian
cancer has recently been proven to be able to reduce
tumor growth and angiogenesis [33,34]. Our results indi-
cate that targeting ALK1 or ALK2 in high-grade central
chondrosarcoma could represent a strategy to induce
differentiation and repress angiogenesis in these tumors.
Methods
Tissue samples
From a collection of 30 conventional central chondro-
sarcoma cases, 26 fresh frozen tumor samples from the
archives of the Department of Pathology of the Leiden
University Medical Center and from the tumor bank of
the Orthopaedic University Hospital Heidelberg, includ-
ing 10 grade I, 10 grade II and 6 grade III tumors, were
available for gene expression analysis. For immunohisto-
chemical analysis, from the same collection of central
tumors, formalin-fixed, paraffin-embedded material from
27 cases including 10 grade I, 11 grade II and 6 grade III
tumors was retrieved from the files of the LeidenUniversity Medical Center. In 23 of the cases, both gene
expression and immunohistochemical analysis were per-
formed. Histological grading was performed for all cases
according to Evans by the same pathologist to avoid
interobserver variability [35]. Except for one case of
Ollier disease, all chondrosarcomas analyzed were soli-
tary. Fresh frozen normal articular cartilage samples
(n=6) obtained from patients undergoing amputation
were used as normal controls for gene expression ana-
lysis. Specimens from Leiden were handled according to
the ethical guidelines described in "Code for Proper Sec-
ondary Use of Human Tissue in The Netherlands" of the
Dutch Federation of Medical Scientific Societies. For the
cases from Heidelberg, the study was approved by the
local ethics committee (medical faculty of Heidelberg)
and informed consent was obtained from all individuals
included in the study.RNA isolation and quantitative real-time polymerase
chain reaction
All tissue samples were processed centrally in one lab
following the same protocol. Haematoxylin and eosin-
stained frozen sections were used to ensure the presence
of at least 70% of tumor cells in the material used for
RNA isolation. Shock-frozen tumor and cartilage tissue
was pulverized mechanically and consecutively dissolved
in lysis/binding buffer for direct poly(A)+-mRNA isola-
tion using oligo-d(T)-coupled beads (Dynabeads; Invitro-
gen). mRNA was subjected to first strand cDNA synthesis
using reverse transcriptase (Sensiscript, Qiagen, Hilden,
Germany) and oligo-d(T) primers. Expression levels of in-
dividual genes were analyzed by quantitative RT-PCR
(Lightcycler, Roche). Aliquots of first-stranded cDNA
were amplified using gene-specific primer sets (Table 2)
obtained from Eurofins (Ebersberg, Germany) and real-
time fluorimetric intensity of SYBR green I was monitored.
The candidate normalization genes described for gene ex-
pression analysis of chondrosarcoma [21] SRPR, CPSF6,
CAPNS1 and HNRPH1 were used as reference. For each
gene, the number of cDNA copies was correlated with the
apparent threshold cycle (Ct). Building the difference be-
tween Ct of the gene of interest and the mean Ct of the
reference genes for each sample gave ΔCt values that were
expressed as a percentage of reference genes. Melting
curves and agarose gel electrophoresis of the PCR products
were used for quality control.Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [36]. Details of primary antibodies are described
in Table 3. As negative controls, slides were incubated
with PBS/BSA 1% instead of primary specific antibodies.
An IHC protocol optimized for cartilaginous tissue was
Table 2 Primer sets used for quantitative RT-PCR analysis








ACVRL1 ALK1 CTGGACATCGGCAACAAC ACACCACCTTCTTCATGTC
ACVR1 ALK2 TGGCTTCCACGTCTACCA GCGAACACTACAGAGAGAA
BMPR1A ALK3 TATGGAGAAGTATGGATGGG GAACCTGTACCTTTAATGTCT
TGFBR1 ALK5 ATTACCAACTGCCTTATTATGA CATTACTCTCAAGGCTTCAC
BMPR2 TGGGATAGGTGAGAGTAGA GAGGGAGGAGTGGTAGTT
TGFBR2 ATGGAGGCCCAGAAAGATG GACTGCACCGTTGTTGTCAG
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was performed using citrate buffer, pH6.0 at 98°C for 10
minutes in a microwave followed by cooling down for
2 h. The antibodies were incubated over night at room
temperature. They were visualized using the DAB+
substrate-chromogen system (Dako, Heverlee, Belgium).
Evaluation and scoring
Semi quantitative scoring of immunohistochemical
staining for phosphorylated Smad1/5/8 (pSmad1/5/8),
phosphorylated Smad2 (pSmad2) and endoglin was per-
formed as described previously [36]. Slides were evalu-
ated blinded towards clinicopathological data. In short,
staining intensities (0 = negative, 1 = weak, 2 = moder-
ate, and 3 = strong intensity) and the percentage of posi-
tive cells (0 = 0%, 1 = 1–24%, 2 = 25–49%, 3 = 50–74%,
and 4 = 75–100% positive) were assessed. For statistical
analysis slides were scored as “high expression” when
the sum score of the staining intensity and the percent-
age of positive cells were greater than 3.
Cell line typing
Early and late passages of the cell lines SW1353 [37] and
JJ012 [38] were tested for their STR loci using the
Powerplex CellIDTM system (Promega) in order toTable 3 Antibodies used for immunohistochemical analysis
Antigen Manufacturer Mono-/polyclonal
phospho-Smad1 (Ser463/465) Cell signaling polyclonal rabbit IgG
/Smad5 (Ser463/465)
/Smad8 (Ser426/428)
phospho-Smad2 (Ser465/467) Cell signaling monoclonal rabbit IgG1
endoglin / CD105 R&D systems polyclonal goat IgGobtain a genetic profile. For SW1353, the genetic profiles
according to these loci were identical to the profile sub-
mitted to the DSMZ database (www.dsmz.de). For JJ012
no genetic profile is submitted to the DSMZ database.
Early and late passage had identical profiles and did not
match with any other cell line in the DSZM database.
Plasmids
The BMP-responsive element (BRE)-luciferase construct
that drives a luciferase gene was obtained from Prof. ten
Dijke [39]. The TGFβ pathway responsive plasmid con-
taining (CAGA)12-luciferase reporter, which is exclu-
sively activated by TGF-β-induced complex, has been
described previously [40]. pRL-CAGGS expresses Renilla
luciferase under a constitutive CAGGS promoter and
was obtained from Promega.
Manipulation of TGFβ- and BMP pathways
TGFβ activity is inhibited by SB-431542 (Tocris Bio-
science) at different concentrations (0.1, 1 and 10 μM)
and stimulated by TGFβ1 (Sigma) (0.5, 2.5 and 5 ng/ml).
BMP activity is manipulated by LDN-193189 (Stemgent
Inc.) (10, 100 and 200 nm) and BMP4 (R&D systems).
Mouse osteoblastic cells C2C12 were used as positive
control for TGFβ and BMP activity. Untreated andStaining Positive control Blocking Concentration
nucleus colon no 1:200
nucleus kidney 10% normal goat
serum, 30’
1:50
cytoplasmic tonsil no 1:800
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tivity in the same range as chondrosarcoma cells.
Proliferation assay
The number of viable cells was determined by using a
Cell Titer-96 Aqueous One Solution Cell Proliferation
Assay (MTS) from Promega, Madison, USA. Cells were
seeded at a density of 2000 cells per well in 96-well flat-
bottom plates. The next day, medium was replaced by
fresh medium containing drug as indicated or DMSO,
each condition in triplicate. The MTS assay was per-
formed according to the manufacturer’s instructions and
absorbance was measured at 490 nm using a Victor3
Multilabel Counter 1420–042 (Perkin Elmer, MA, USA).
Transient transfection and luciferase assay
Cells were seeded at a density of 5000 cells per well in
96-well flat-bottom plates. Next day, 100μl transfection
complex was prepared with 1.95 μg of each plasmid
driving luciferase expression from the corresponding
BMP or TGFβ responsive promoters and 0.05 μg of
pRL-CAGGS, an internal control for transfection effi-
ciency driving renilla expression from a constitutive pro-
moter. 5μl of the mix was added per well using Fugene
HD transfection reagent (Roche, Mannheim, Germany)
according to the manufacturer’s protocol. After 24 hours
the medium was replaced by medium supplemented
with 300ng/ml BMP4 or 10, 100, 200nM LDN-193189.
After 24 h incubation, cells were harvested and lucifer-
ase activity was measured with a Victor 3 Multilabel
Counter 1420–042 using the Dual-luciferase Reporter
Kit (Promega). The ratio of firefly to renilla fluorescence
was calculated to normalize reporter activity to the
transfection efficiency. Three independent transfections
were performed, each in triplicate.
Statistical analysis
Data analysis was performed with SPSS for Windows
(SPSS, Chicago, USA). Median values of gene expression
levels as assessed by quantitative RT-PCR were calcu-
lated. The Mann–Whitney test was chosen to evaluate
significant differences in gene expression levels between
sample groups. For the comparison of gene expression
levels between chondrosarcoma of different grades
and between cartilage samples and chondrosarcoma
in Figure 1, the bonferroni correction was used and
p<0.0125 was considered significant. For the analysis of
immunohistochemical data, the Pearson chi-square test/
Fisher’s exact test, two-sided was used for comparison
between low- and high-grade chondrosarcoma. Since the
number of samples of grade III chondrosarcoma (n=6)
alone was considered too low for this test the clinically
more relevant comparison between low-grade (grade I)
and high-grade (grade II + III) chondrosarcoma wasconsidered. Total survival and metastasis-free survival
curves based on Kaplan–Meier estimates were compared
using log rank test. For all tests a p value <0.05 was con-
sidered significant.
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